Onpoint Vision

OnPoint Vision, Inc. Opens Phase I Enrollment of Approved IDE.

by

PRESS RELEASE ALISO VIEJO, Calif., March 25, 2024, OnPoint Vision Inc, a privately held ophthalmic medical device company, announced open enrollment of approved Investigational Device Exemption (IDE) begin Phase I of their pivotal clinical trial of the AccuraSee™ Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG) for secondary implantation in the capsular bag with a pre-existing … Read more

OnPoint Vision Sees Clear Road Ahead

by

OnPoint Vision has developed a 4.5 millimeter lens to help treat macular degeneration. The Food and Drug Administration initially accepted Kevin Cady’s proposal for an implantable lens to correct vision after cataract surgery. Then the FDA switched course by asking Cady to consider a different unmet need—patients suffering from macular degeneration, with vision 20/80 or … Read more

FDA Approval of OnPoint Vision’s Investigational Device Exemption (IDE) Application to Begin Phase I

by

PRESS RELEASE ALISO VIEJO, Calif., October 26, 2023, OnPoint Vision Inc, a privately held ophthalmic medical device company, announced the FDA approval of their Investigational Device Exemption (IDE) application to begin Phase I of their pivotal clinical trial of the AccuraSee™ Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG) for secondary implantation in the capsular bag … Read more

KEVIN CADY
President & CEO

Kevin Cady is the CEO and Founder of OnPoint Vision™, a refractive company that designs, develops & manufactures intraocular lens implants, most specifically the AccuraSee™ Intraocular Pseudophakic Contact Lens (AKA: CadyLens) designed to fine-tune the refractive error of the pseudophakic eye as well as deliver vision recovery for patients who have experienced a decline in vision due to age-related retinal pathologies.  Prior to forming OnPoint Vision™, Mr. Cady joined Refocus Group in 2015 as Vice President of Marketing & Business Development. From 2011 to 2014, Mr. Cady was the Regional Business Director for WaveTec Vision Systems, where he was responsible for the marketplace expansion of the Optiwave Refractive Analysis (ORA) system to ophthalmic surgeons. Prior to joining WaveTec Vision Systems, Mr. Cady was the Area Vice President of Sales for Bausch Lomb Surgical, after the company acquired Eyeonics. Mr. Cady has over 30 years in the ophthalmic industry theatre with extensive knowledge and experience in both the development of ophthalmic pharmacologic agents and medical device product line.

Mr. Cady has a Bachelor of Science Degree in Economics from Illinois State University. He is credentialed with over 35 patents worldwide with the  invention of the CadyLens, an Intraocular Pseudophakic Contact Lens (IOPCL) as well as related surgical instruments and medical devices.